Associate Physician Nephrology, Massachusetts General Hospital

Clinicn Investigator, Assc Prf Nephrology - Renal Assoc, Mass General Research Institute

Associate Professor of Medicine Harvard Medical School

MMSCI Co-Course Director, CI 714, Fall 2025 Medicine, Harvard Medical School

MD University of Vermont College of Medicine 2007

acute kidney injury; carbamates; carbamylation; carnitine; chronic kidney disease; end stage kidney disease; hiv infections; kidney cortex necrosis; kidney failure chronic; morbidity; picea; renal dialysis; renal metabolomics; serum albumin; survival rate My research focuses on understanding the fundamental causes of the excess morbidity and mortality seen in patients with chronic and end-stage kidney disease in an effort to develop new targeted therapies. We have linked a protein modification known as carbamylation to several adverse outcomes such as resistance to erythropoietin and mortality in patients with kidney disease.  Similarly, using high throughput screening, we have identified a number of novel metabolite derangements associated with cardiovascular disease in dialysis patients.  We are now studying ways to correct these metabolic disturbances and determine, through clinical trials, if doing so results in improved patient outcomes.